SEER Seer

Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease

REDWOOD CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it ranked No. 57 on the ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. Seer grew 2,440% during this period.

Seer’s President and CFO, David Horn, credits increased adoption of Seer’s Proteograph Product Suite, as well as new discoveries made by its customers across neurodegenerative disease, cancer, and metabolic disease, with the company’s 2,440% revenue growth.

"This has been an exciting year for Seer, from the launch of our technology access center in Europe, to seeing our Proteograph platform used by astronauts on the SpaceX Inspiration4 mission, to the recent announcement of our co-marketing and sales agreement with Thermo Fisher Scientific,” Horn said. “We’re proud to see continuing validation of our work providing customers and the broader scientific community with the power to enable deep proteomic insights at a scale and price point that hasn’t been possible before."

Seer previously ranked No. 5 as a Technology Fast 500 award winner for 2023.

Overall, 2024 Technology Fast 500 companies achieved revenue growth ranging from 201% to 153,625% over the three-year time frame, with an average growth rate of 1,981% and median growth rate of 460%.

About the 2024 Deloitte Technology Fast 500:

Now in its 30th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Seer:

Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit .

Media Contact: Patrick Schmidt

Investor Contact: Carrie Mendivil

About Deloitte:

Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 8,500 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an by creating trust and confidence in a more equitable society. We leverage our unique blend of business acumen, command of technology, and strategic technology alliances to advise our clients across industries as they . Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s approximately 460,000 people worldwide connect for impact at .

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see  to learn more about our global network of member firms.



EN
21/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Seer

 PRESS RELEASE

Seer Reports First Quarter 2025 Financial Results and Reiterates Full ...

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook Revenue grew 37%, driven by increased product sales and service revenue REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with ...

 PRESS RELEASE

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

Seer to Report First Quarter 2025 Financial Results on May 13, 2025 REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay ...

 PRESS RELEASE

Seer Reports Fourth Quarter and Full Year 2024 Financial Results and P...

Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook Validated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Suite with growing demand for Seer Technology Access Center (STAC) REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Achieved revenue of ...

 PRESS RELEASE

Seer to Participate in the TD Cowen 45th Annual Health Care Conference

Seer to Participate in the TD Cowen 45th Annual Health Care Conference REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 45th Annual Healthcare Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Tuesday, March 4th at 11:50 a.m. Eastern Time / 8:50 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s...

 PRESS RELEASE

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Resea...

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025 Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer’s Proteograph™ Product Suite REDWOOD CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will showcase new findings at the 21st Annual US Hum...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch